IMVT
$25.10
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases.
Recent News
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?
This clinical-stage biotech develops antibody therapies targeting autoimmune diseases, with a lead candidate in Phase II trials.
Assessing Immunovant (IMVT) Valuation After Recent Share Price Weakness
Immunovant in Context: Recent Performance Snapshot Immunovant (IMVT) has been under pressure recently, with the stock showing a 2.3% decline over the past day and weaker returns over the week, month, and past 3 months, despite a stronger 1 year gain. See our latest analysis for Immunovant. At a share price of US$24.41, Immunovant has seen short term share price pressure, including a 7 day share price return of negative 8.44%. In contrast, longer term total shareholder returns, such as the 1...
Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish
This biotech specializes in antibody therapies for autoimmune diseases, with its lead candidate progressing through trials.
Truth Social Stock Down 50% as One Investor Sells Off Nearly 800,000 Shares
This digital media firm operates Truth Social, a platform delivering internet content and information services to online audiences.
Immunovant Stock Surges 17% in 3 Months: What's Driving It?
IMVT gains 17% in three months as IMVT-1402 advances across autoimmune trials, with multiple data readouts due in 2026-2027, and $994.5M cash backing development.